Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata

被引：0
|
作者：
Moe Sakakibara
Harunari Shimoyama
Mami Nomura
Chikako Nakashima
Megumi Hirabayashi
Yoshihiro Sei
Yoshihiro Kuwano
机构：
[1] Teikyo University School of Medicine,Department of Dermatology, Mizonokuchi Hospital
来源：
European Journal of Dermatology | 2019年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：436 / 437
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
    Crispin, Milene Kennedy
    Ko, Justin M.
    Craiglow, Brittany G.
    Li, Shufeng
    Shankar, Gautam
    Urban, Jennifer R.
    Chen, James C.
    Cerise, Jane E.
    Jabbari, Ali
    Winge, Marten C. G.
    Marinkovich, M. Peter
    Christiano, Angela M.
    Oro, Anthony E.
    King, Brett A.
    JCI INSIGHT, 2016, 1 (15):
  • [32] Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata
    Chen, Ying
    Xu, Qiuyun
    Lv, Xiaoqing
    Zhuang, Zheyu
    Bao, Siyi
    Mao, Jing
    Gong, Ting
    Ji, Chao
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2025,
  • [33] Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
    Dai, Ying-Xiu
    Yeh, Chen-Pu
    Chen, Chih-Chiang
    DERMATOLOGICA SINICA, 2020, 38 (01) : 3 - 8
  • [34] High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast
    Bethke, T. D.
    Lahu, G.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (01) : 51 - 57
  • [35] The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys
    Losco, PE
    Evans, EW
    Barat, SA
    Blackshear, PE
    Reyderman, L
    Fine, JS
    Bober, LA
    Anthes, JC
    Mirro, EJ
    Cuss, FM
    TOXICOLOGIC PATHOLOGY, 2004, 32 (03) : 295 - 308
  • [36] A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
    Daniela Mikhaylov
    Ana Pavel
    Christopher Yao
    Grace Kimmel
    John Nia
    Peter Hashim
    Anjali S. Vekaria
    Mark Taliercio
    Giselle Singer
    Rachel Karalekas
    Danielle Baum
    Yasaman Mansouri
    Mark G. Lebwohl
    Emma Guttman-Yassky
    Archives of Dermatological Research, 2019, 311 : 29 - 36
  • [37] A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
    Mikhaylov, Daniela
    Pavel, Ana
    Yao, Christopher
    Kimmel, Grace
    Nia, John
    Hashim, Peter
    Vekaria, Anjali S.
    Taliercio, Mark
    Singer, Giselle
    Karalekas, Rachel
    Baum, Danielle
    Mansouri, Yasaman
    Lebwohl, Mark G.
    Guttman-Yassky, Emma
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2019, 311 (01) : 29 - 36
  • [38] Successful treatment of recalcitrant pemphigus vulgaris with the phosphodiesterase 4 inhibitor apremilast
    Meier, K.
    Holstein, J.
    Solimani, F.
    Waschke, J.
    Ghoreschi, K.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 (03) : E26 - E27
  • [39] Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis
    Bissonnette, Robert
    Pariser, David M.
    Wasel, Norman R.
    Goncalves, Joana
    Day, Robert M.
    Chen, Rongdean
    Sebastian, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (01) : 99 - 105
  • [40] Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
    Ikumi, Kyoko
    Torii, Kan
    Sagawa, Yoko
    Kanayama, Yoshifumi
    Nakada, Aya
    Nishihara, Haruna
    Morita, Akimichi
    JOURNAL OF DERMATOLOGY, 2022, 49 (04): : E125 - E126
12345